Public list: BIO 2016 (619) Pharma Startups (4733)
Akebia Therapeutics is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the t...Show all
Company (IPO / Went public)
Phone: 617-871-2098
245 First Street
Suite 1400
Cambridge, 02142
Massachusetts, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Akebia Therapeutics | $195.3M | Mar 21, 2014 |
| Humanetics Corporation | $0.6M | Oct 10, 2017 |
| Affinium Pharmaceuticals | $44.9M | Sep 12, 2013 |
| See all 33 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | Aug 24, 2015 | Oct 03, 2017 | Patent |
| Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2014 | Jul 11, 2017 | Patent |
| Prolyl hydroxylase inhibitors and methods of use | Sep 15, 2015 | Mar 21, 2017 | Patent |
| Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | Jun 05, 2012 | Sep 29, 2015 | Patent |
| Prolyl hydroxylase inhibitors and methods of use | Oct 24, 2013 | Jan 27, 2015 | Patent |
Download PDF